1. Тюзиков И.А. Эректильная дисфункция в современной клинической практике: нужны ли взаимодействия кардиолога и уролога? Consilium Medicum. 2014; 16 (5): 117–22. / Tiuzikov I.A. Erektil'naia disfunktsiia v sovremennoi klinicheskoi praktike: nuzhny li vzaimodeistviia kardiologa i urologa? Consilium Medicum. 2014; 16 (5): 117–22. [in Russian]
2. Kleinman KP, Feldman HA, Johannes CB et al. A new surrogate variable for erectile dysfunction status in the Massachusetts Male Aging Study. J Clin Epidemiol 2000; 53: 71–8.
3. Johannes CB, Araujo AB, Feldman HA et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results fr om the Massachusetts Male Aging Study. Urology 2000; 163: 460–3.
4. Корнеев И.А. Эректильная дисфункция: особенности диагностики и медикаментозного лечения мужчин с сопутствующими заболеваниями. Consilium Medicum. 2015; 17 (7): 24–8. / Korneev I.A. Erectile dysfunction: features of diagnostics and medical treatment of men with comorbidities. Consilium Medicum. 2015; 17 (7): 24–8. [in Russian]
5. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58 (13): 1378–85.
6. Gazzaruso C, Coppola A, Montalcini T et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 2011; 40 (2): 273–9.
7. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Athewscler Rep 2002; 4: 397–401.
8. Kloner RA, Mullin SH, ShookT et al. Erectile dysfunction in the cardiac patient: How common and should we treat? Urology 2003; 170: 46–50.
9. Клонер Р.А. Эректильная дисфункция у кардиологических больных. Рус. мед. журн. 2008; 20: 1329–32. / Kloner R.A. Erektil'naia disfunktsiia u kardiologicheskikh bol'nykh. Rus. med. zhurn. 2008; 20: 1329–32. [in Russian]
10. Приказ Министерства здравоохранения РФ от 9 ноября 2012 г. №778н «Об утверждении стандарта первичной медико-санитарной помощи при эректильной дисфункции». Система ГАРАНТ. http://base.garant.ru/70304262/#friends#ixzz47QTuDwD5 / Prikaz Ministerstva zdravookhraneniia RF ot 9 noiabria 2012 g. №778n “Ob utverzhdenii standarta pervichnoi mediko-sanitarnoi pomoshchi pri erektil'noi disfunktsii”. Sistema GARANT. http://base.garant.ru/70304262/#friends#ixzz47QTuDwD5 [in Russian]
11. Верткин А.Л., Лоран О.Б., Тополянский А.В. и др. Эректильная дисфункция у кардиологических и терапевтических пациентов. Рус. мед. журн. 2001; 25: 1308–17. / Vertkin A.L., Loran O.B., Topolianskii A.V. i dr. Erektil'naia disfunktsiia u kardiologicheskikh i terapevticheskikh patsientov. Rus. med. zhurn. 2001; 25: 1308–17. [in Russian]
12. Бакшеев В.И., Коломоец Н.М., Гончарук А.И. Синдром эректильной дисфункции в практике терапевта. Клин. медицина. 2005; 3: 16–23. / Baksheev V.I., Kolomoets N.M., Goncharuk A.I. Sindrom erektil'noi disfunktsii v praktike terapevta. Klin. meditsina. 2005; 3: 16–23. [in Russian]
13. Трухан Д.И., Филимонов С.Н. Заболевания почек и мочевых путей: клиника, диагностика и лечение. Новокузнецк: Полиграфист, 2017. / Trukhan D.I., Filimonov S.N. Zabolevaniia pochek i mochevykh putei: klinika, diagnostika i lechenie. Novokuznetsk: Poligrafist, 2017. [in Russian]
14. Кульчавеня Е.В., Бреусов А.А. Роль силденафила в жизни мужчины и женщины. РМЖ. 2016; 23: 1542–5. / Kul'chavenia E.V., Breusov A.A. Rol' sildenafila v zhizni muzhchiny i zhenshchiny. RMZh. 2016; 23: 1542–5. [in Russian]
15. Трухан Д.И., Макушин Д.Г. Эректильная дисфункция: актуальные вопросы диагностики и лечения на этапе оказания первичной специализированной и медико-санитарной помощи. Consilium Medicum. 2016; 18 (7): 66–71. / Trukhan D.I., Makushin D.G. Erectile disfunction: current issues diagnosis and treatment of primary stage and specialized health care. Consilium Medicum. 2016; 18 (7): 66–71. [in Russian]
16. Верткин А.Л., Моргунов Л.Ю. Лечение эректильной дисфункции: эффекты силденафила. Consilium Medicum. 2014; 16 (2): 63–6. / Vertkin A.L., Morgunov L.Iu. Lechenie erektil'noi disfunktsii: effekty sildenafila. Consilium Medicum. 2014; 16 (2): 63–6. [in Russian]
17. Ефремов Е.А., Касатонова Е.В., Мельник Я.И. Применение силденафила цитрата при эректильной дисфункции различной этиологии. Урология. 2015; 2: 117–21. / Efremov E.A., Kasatonova E.V., Mel'nik Ia.I. Primenenie sildenafila tsitrata pri erektil'noi disfunktsii razlichnoi etiologii. Urologiia. 2015; 2: 117–21. [in Russian]
18. Камалов А.А., Дорофеев С.Д., Ефремов Е.А. Кардиоваскулярные аспекты эректильной дисфункции. Consilium Medicum. 2004; 6 (5): 360–5. / Kamalov A.A., Dorofeev S.D., Efremov E.A. Kardiovaskuliarnye aspekty erektil'noi disfunktsii. Consilium Medicum. 2004; 6 (5): 360–5. [in Russian]
19. Рафальский В.В., Багликов А.Н. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5-го типа у пациентов с сердечно-сосудистыми заболеваниями. Пробл. эндокринологии. 2010; 6: 63–72. / Rafal'skii V.V., Baglikov A.N. Podkhody k ratsional'nomu vyboru ingibitorov fosfodiesterazy 5-go tipa u patsientov s serdechno-sosudistymi zabolevaniiami. Probl. endokrinologii. 2010; 6: 63–72. [in Russian]
20. Корнеев И.А. Терапия ИФДЭ5 при эректильной дисфункции и вопросы сердечно-сосудистой безопасности. Урологические ведомости. 2015; 17 (2): 28–30. / Korneev I.A. Terapiia IFDE5 pri erektil'noi disfunktsii i voprosy serdechno-sosudistoi bezopasnosti. Urologicheskie vedomosti. 2015; 17 (2): 28–30. [in Russian]
21. Гамидов С.И., Овчинников Р.И., Попова А.Ю. Новые аспекты применения силденафила цитрата в лечении эректильной дисфункции. Consilium Medicum. 2014; 16 (5): 112–6. / Gamidov S.I., Ovchinnikov R.I., Popova A.Iu. Novye aspekty primeneniia sildenafila tsitrata v lechenii erektil'noi disfunktsii. Consilium Medicum. 2014; 16 (5): 112–6. [in Russian]
22. Дамулин И.В., Есилевский Ю.М. Эректильная дисфункция: современное состояние проблемы. Урология. 2014; 16 (3): 95–101. / Damulin I.V., Esilevskii Iu.M. Erektil'naia disfunktsiia: sovremennoe sostoianie problemy. Urologiia. 2014; 16 (3): 95–101. [in Russian]
23. Корнеев И.А. Подбор дозы силденафила цитрата для мужчин с эректильной дисфункцией: персонифицированый подход. Урология. 2015; 4: 108–11. / Korneev I.A. Podbor dozy sildenafila tsitrata dlia muzhchin s erektil'noi disfunktsiei: personifitsirovanyi podkhod. Urologiia. 2015; 4: 108–11. [in Russian]
24. Ефремов Е.А., Касатонова Е.В., Мельник Я.И. Современный взгляд на применение силденафила цитрата. Эксперим. и клин. урология. 2015; 1: 60–5. / Efremov E.A., Kasatonova E.V., Mel'nik Ia.I. Sovremennyi vzgliad na primenenie sildenafila tsitrata. Eksperim. i klin. urologiia. 2015; 1: 60–5. [in Russian]
25. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8 (12): 3418–32.
26. McCullough AR. Four-year review of sildenafil citrate. Rev Urol 2002; 4 (Suppl. 3): S26–38.
27. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002; 7: 435–46.
28. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
29. Пчелинцев М.В. Индивидуальное дозирование ингибиторов фосфодиэстеразы 5-го типа как путь повышения эффективности и безопасности медикаментозного лечения эректильной дисфункции. Consilium Medicum. 2014; 16 (7): 11–6. / Pchelintsev M.V. Individual'noe dozirovanie ingibitorov fosfodiesterazy 5-go tipa kak put' povysheniia effektivnosti i bezopasnosti medikamentoznogo lecheniia erektil'noi disfunktsii. Consilium Medicum. 2014; 16 (7): 11–6. [in Russian]
30. Carson CC. Sildenafil: a 4-yearupdate in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4 (6): 488–96.
31. Goldstein I, Lue TF, Padma-Nathan H et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. J Urol 2002; 167: 1197–203.
32. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
33. Wagner G, Montorsi F, Auerbach S et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113–9.
34. Carson CC, Burnett AL, Levine LA et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60 (2. Suppl. 2): 12–27.
35. Leslie SJ, Atkins G, Oliver JJ, Webb DJ. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004; 76 (4): 365–70.
36. Описание лекарственного препарата Виагра® (Viagra®). https://www.vidal.ru/drugs/viagra__2225 / Opisanie lekarstvennogo preparata Viagra® (Viagra®). https://www.vidal.ru/drugs/viagra__2225 [in Russian]
37. Bhalla A. Is sildenafil safe with alcohol? J Assoc Physicians India 2003; 51: 1125–6.
38. Smith RG. An appraisal of potential drug interactions in cigarette smokers and alcohol drinkers. J Am Podiatr Med Assoc 2009; 99 (1): 81–8.
39. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafi l citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–5.
40. Гамидов С.И., Овчинников Р.И., Попова А.Ю., Ижбаев С.Х. Ингибиторы фосфоди­эстеразы 5-го типа в лечении эректильной дисфункции: прошлое, настоящее и будущее. Урология. 2017; 1: 103–7. / Gamidov S.I., Ovchinnikov R.I., Popova A.Iu., Izhbaev S.Kh. Ingibitory fosfodiesterazy 5-go tipa v lechenii erektil'noi disfunktsii: proshloe, nastoiashchee i budushchee. Urologiia. 2017; 1: 103–7. [in Russian]
41. Gil A, Martinez E, Oyaguez I et al. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–47.
42. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762–7.
43. Петров С.Б., Кушниренко Н.П., Кушниренко К.Н. Силденафила цитрат (Виагра) и улучшение показателей качества жизни у мужчин. Клин. фармакология и терапия. 2007; 1: 85–9. / Petrov S.B., Kushnirenko N.P., Kushnirenko K.N. Sildenafila tsitrat (Viagra) i uluchshenie pokazatelei kachestva zhizni u muzhchin. Klin. farmakologiia i terapiia. 2007; 1: 85–9. [in Russian]
44. Fowler CJ, Miller JR, Sharief MK et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 700–5.
45. Диденко В.И. Преимущество лечения силденафилом эректильной дисфункции у пациентов в позднем онтогенезе. Урологические ведомости. 2016; 2: 23–7. / Didenko V.I. Preimushchestvo lecheniia sildenafilom erektil'noi disfunktsii u patsientov v pozdnem ontogeneze. Urologicheskie vedomosti. 2016; 2: 23–7. [in Russian]
46. Hoffman BM, Sherwood A, Smith PJ et al. Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men. J Int Impot Res 2010; 22 (1): 30–5.
47. Vlachopoulos C, Jackson G, Stefanadis C et al. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013; 34: 2034–46.
48. Ефремов Е.А., Касатонова Е.В., Мельник Я.И., Симаков В.В. Современные аспекты применения силденафила. Урология. 2016; 5: 120–9. / Efremov E.A., Kasatonova E.V., Mel'nik Ia.I., Simakov V.V. Sovremennye aspekty primeneniia sildenafila. Urologiia. 2016; 5: 120–9. [in Russian]
49. Cakir O. The frequencies and characteristics of men receiving medical intervention for erectile dysfunction: Analysis of 6.2 million patients. 28-th Annual EAU congress, 15–19 March, 2013. Milan. Italy, abst. №126.
50. Гамидов С.И., Овчинников Р.И., Попова А.Ю. Новые аспекты применения силденафила в лечении эректильной дисфункции. Мед. совет. 2015; 11: 54–9. / Gamidov S.I., Ovchinnikov R.I., Popova A.Iu. Novye aspekty primeneniia sildenafila v lechenii erektil'noi disfunktsii. Med. sovet. 2015; 11: 54–9. [in Russian]
51. Arruda-Olson AM, Mahoney DW, Nehra A et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized, crossover trial. JAMA 2002; 287: 719–25.
52. Balhara Y.P., Sarkar S., Gupta R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian J Endocrinol Metab 2015; 19 (4): 451–61.
53. Трухан Д.И., Викторова И.А. Болезни почек и мочевых путей. М.: Практическая медицина, 2011. / Trukhan D.I., Viktorova I.A. Bolezni pochek i mochevykh putei. M.: Prakticheskaia meditsina, 2011. [in Russian]
54. Cheitlin MD, Hutter AM, Brindis RG et al. ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. Am Coll Cardiol 1999; 33: 273–82.
55. DeBusk R, Drory Y, Goldstein I et al. Management of sexual dysfunction in patients with cardiovascular disease: recomendations of the Princeton Consensus Panel. Am Cardiol 2000; 86: 175–81.
56. Рекомендации по лечению стабильной ишемической болезни сердца. ESC 2013. http://www.scardio.ru/content/Guidelines/IBS_rkj_7_14.pdf / Rekomendatsii po lecheniiu stabil'noi ishemicheskoi bolezni serdtsa. ESC 2013. http://www.scardio.ru/content/Guidelines/IBS_rkj_7_14.pdf [in Russian]
57. Gupta BP, Murad MH, Clifton MM et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and metaanalysis. Arch Intern Med 2011; 171: 1797–803.
58. Kloner R, Padma-Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005; 17: 209–15.
59. Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. Am J Hematol 2001; 14: 70–3.
60. Kloner RA, Mitchell MI, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol 2002; 167 (4): 176–7.
61. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). http://scardio.ru/content/Guidelines/SSHF-Guidelines-rev.4.0.1.pdf / Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). http://scardio.ru/content/Guidelines/SSHF-Guidelines-rev.4.0.1.pdf [in Russian]
62. Llisterri JL, Lozano Vidal JV, Aznar Vicente J et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321 (5): 336–41.
63. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002; 4 (3): 202–10.
64. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64 (2): 240–55.
65. Зырянов С.К. Применение ингибиторов фосфодиэстеразы 5-го типа в лечении пациентов с разными соматическими заболеваниями: позиция клинициста (лекция). Consilium Medicum. 2014; 10: 131–5. / Zyrianov S.K. Primenenie ingibitorov fosfodiesterazy 5-go tipa v lechenii patsientov s raznymi somaticheskimi zabolevaniiami: pozitsiia klinitsista (lektsiia). Consilium Medicum. 2014; 10: 131–5. [in Russian]
66. Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: wh ere does it fit in? Curr Urol Rep 2013; 14 (4): 269–78.
67. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9 (1): 134–41.
68. Hakky TS, Jain L. Current use of phosphodiesterase inhibitors in urology. Turk J Urol 2015; 41 (2): 88–92.
69. Gumrah A, Tanidir Y, Tinay I et al. The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction. Neurourol Urodyn 2016. DOI: 10.1002/nau.23155 [Epub ahead of print]
70. Трухан Д.И. Оригиналы и генерики: перезагрузка в свете экономического кризиса. Справочник поликлинического врача. 2012; 4: 32–6. / Trukhan D.I. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Handbook for Practitioners Doctors. 2012; 4: 32–6. [in Russian]
71. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 15 (11): 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
72. Описание лекарственного препарата Визарсин® (Vizarsin®). URL: https://www.vidal.ru/drugs/vizarsin__30488 / Opisanie lekarstvennogo preparata Vizarsin® (Vizarsin®). URL: https://www.vidal.ru/drugs/vizarsin__30488 [in Russian]
73. Визарсин® Ку-таб (Vizarsin® Q-tab), инструкция по применению. URL: https://www.vidal.ru/drugs/vizarsin_q-tab__42724 / Vizarsin® Ku-tab (Vizarsin® Q-tab), instruktsiia po primeneniiu. URL: https://www.vidal.ru/drugs/vizarsin_q-tab__42724 [in Russian]

________________________________________________

1. Tiuzikov I.A. Erektil'naia disfunktsiia v sovremennoi klinicheskoi praktike: nuzhny li vzaimodeistviia kardiologa i urologa? Consilium Medicum. 2014; 16 (5): 117–22. [in Russian]
2. Kleinman KP, Feldman HA, Johannes CB et al. A new surrogate variable for erectile dysfunction status in the Massachusetts Male Aging Study. J Clin Epidemiol 2000; 53: 71–8.
3. Johannes CB, Araujo AB, Feldman HA et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results fr om the Massachusetts Male Aging Study. Urology 2000; 163: 460–3.
4. Korneev I.A. Erectile dysfunction: features of diagnostics and medical treatment of men with comorbidities. Consilium Medicum. 2015; 17 (7): 24–8. [in Russian]
5. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58 (13): 1378–85.
6. Gazzaruso C, Coppola A, Montalcini T et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 2011; 40 (2): 273–9.
7. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Athewscler Rep 2002; 4: 397–401.
8. Kloner RA, Mullin SH, ShookT et al. Erectile dysfunction in the cardiac patient: How common and should we treat? Urology 2003; 170: 46–50.
9. Kloner R.A. Erektil'naia disfunktsiia u kardiologicheskikh bol'nykh. Rus. med. zhurn. 2008; 20: 1329–32. [in Russian]
10. Prikaz Ministerstva zdravookhraneniia RF ot 9 noiabria 2012 g. №778n “Ob utverzhdenii standarta pervichnoi mediko-sanitarnoi pomoshchi pri erektil'noi disfunktsii”. Sistema GARANT. http://base.garant.ru/70304262/#friends#ixzz47QTuDwD5 [in Russian]
11. Vertkin A.L., Loran O.B., Topolianskii A.V. i dr. Erektil'naia disfunktsiia u kardiologicheskikh i terapevticheskikh patsientov. Rus. med. zhurn. 2001; 25: 1308–17. [in Russian]
12. Baksheev V.I., Kolomoets N.M., Goncharuk A.I. Sindrom erektil'noi disfunktsii v praktike terapevta. Klin. meditsina. 2005; 3: 16–23. [in Russian]
13. Trukhan D.I., Filimonov S.N. Zabolevaniia pochek i mochevykh putei: klinika, diagnostika i lechenie. Novokuznetsk: Poligrafist, 2017. [in Russian]
14. Kul'chavenia E.V., Breusov A.A. Rol' sildenafila v zhizni muzhchiny i zhenshchiny. RMZh. 2016; 23: 1542–5. [in Russian]
15. Trukhan D.I., Makushin D.G. Erectile disfunction: current issues diagnosis and treatment of primary stage and specialized health care. Consilium Medicum. 2016; 18 (7): 66–71. [in Russian]
16. Vertkin A.L., Morgunov L.Iu. Lechenie erektil'noi disfunktsii: effekty sildenafila. Consilium Medicum. 2014; 16 (2): 63–6. [in Russian]
17. Efremov E.A., Kasatonova E.V., Mel'nik Ia.I. Primenenie sildenafila tsitrata pri erektil'noi disfunktsii razlichnoi etiologii. Urologiia. 2015; 2: 117–21. [in Russian]
18. Kamalov A.A., Dorofeev S.D., Efremov E.A. Kardiovaskuliarnye aspekty erektil'noi disfunktsii. Consilium Medicum. 2004; 6 (5): 360–5. [in Russian]
19. Rafal'skii V.V., Baglikov A.N. Podkhody k ratsional'nomu vyboru ingibitorov fosfodiesterazy 5-go tipa u patsientov s serdechno-sosudistymi zabolevaniiami. Probl. endokrinologii. 2010; 6: 63–72. [in Russian]
20. Korneev I.A. Terapiia IFDE5 pri erektil'noi disfunktsii i voprosy serdechno-sosudistoi bezopasnosti. Urologicheskie vedomosti. 2015; 17 (2): 28–30. [in Russian]
21. Gamidov S.I., Ovchinnikov R.I., Popova A.Iu. Novye aspekty primeneniia sildenafila tsitrata v lechenii erektil'noi disfunktsii. Consilium Medicum. 2014; 16 (5): 112–6. [in Russian]
22. Damulin I.V., Esilevskii Iu.M. Erektil'naia disfunktsiia: sovremennoe sostoianie problemy. Urologiia. 2014; 16 (3): 95–101. [in Russian]
23. Korneev I.A. Podbor dozy sildenafila tsitrata dlia muzhchin s erektil'noi disfunktsiei: personifitsirovanyi podkhod. Urologiia. 2015; 4: 108–11. [in Russian]
24. Efremov E.A., Kasatonova E.V., Mel'nik Ia.I. Sovremennyi vzgliad na primenenie sildenafila tsitrata. Eksperim. i klin. urologiia. 2015; 1: 60–5. [in Russian]
25. Corona G, Mondaini N, Ungar A et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8 (12): 3418–32.
26. McCullough AR. Four-year review of sildenafil citrate. Rev Urol 2002; 4 (Suppl. 3): S26–38.
27. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil review of the literature. Eur J Med Res 2002; 7: 435–46.
28. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
29. Pchelintsev M.V. Individual'noe dozirovanie ingibitorov fosfodiesterazy 5-go tipa kak put' povysheniia effektivnosti i bezopasnosti medikamentoznogo lecheniia erektil'noi disfunktsii. Consilium Medicum. 2014; 16 (7): 11–6. [in Russian]
30. Carson CC. Sildenafil: a 4-yearupdate in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4 (6): 488–96.
31. Goldstein I, Lue TF, Padma-Nathan H et al. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. J Urol 2002; 167: 1197–203.
32. Padma-Nathan H, Stecher VJ, Sweeney M et al. Minimal time to successful intercourse after sildenafi l citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 400–3.
33. Wagner G, Montorsi F, Auerbach S et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: M113–9.
34. Carson CC, Burnett AL, Levine LA et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60 (2. Suppl. 2): 12–27.
35. Leslie SJ, Atkins G, Oliver JJ, Webb DJ. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004; 76 (4): 365–70.
36. Opisanie lekarstvennogo preparata Viagra® (Viagra®). https://www.vidal.ru/drugs/viagra__2225 [in Russian]
37. Bhalla A. Is sildenafil safe with alcohol? J Assoc Physicians India 2003; 51: 1125–6.
38. Smith RG. An appraisal of potential drug interactions in cigarette smokers and alcohol drinkers. J Am Podiatr Med Assoc 2009; 99 (1): 81–8.
39. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafi l citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–5.
40. Gamidov S.I., Ovchinnikov R.I., Popova A.Iu., Izhbaev S.Kh. Ingibitory fosfodiesterazy 5-go tipa v lechenii erektil'noi disfunktsii: proshloe, nastoiashchee i budushchee. Urologiia. 2017; 1: 103–7. [in Russian]
41. Gil A, Martinez E, Oyaguez I et al. Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–47.
42. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology 2004; 63: 762–7.
43. Petrov S.B., Kushnirenko N.P., Kushnirenko K.N. Sildenafila tsitrat (Viagra) i uluchshenie pokazatelei kachestva zhizni u muzhchin. Klin. farmakologiia i terapiia. 2007; 1: 85–9. [in Russian]
44. Fowler CJ, Miller JR, Sharief MK et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 700–5.
45. Didenko V.I. Preimushchestvo lecheniia sildenafilom erektil'noi disfunktsii u patsientov v pozdnem ontogeneze. Urologicheskie vedomosti. 2016; 2: 23–7. [in Russian]
46. Hoffman BM, Sherwood A, Smith PJ et al. Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men. J Int Impot Res 2010; 22 (1): 30–5.
47. Vlachopoulos C, Jackson G, Stefanadis C et al. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013; 34: 2034–46.
48. Efremov E.A., Kasatonova E.V., Mel'nik Ia.I., Simakov V.V. Sovremennye aspekty primeneniia sildenafila. Urologiia. 2016; 5: 120–9. [in Russian]
49. Cakir O. The frequencies and characteristics of men receiving medical intervention for erectile dysfunction: Analysis of 6.2 million patients. 28-th Annual EAU congress, 15–19 March, 2013. Milan. Italy, abst. №126.
50. Gamidov S.I., Ovchinnikov R.I., Popova A.Iu. Novye aspekty primeneniia sildenafila v lechenii erektil'noi disfunktsii. Med. sovet. 2015; 11: 54–9. [in Russian]
51. Arruda-Olson AM, Mahoney DW, Nehra A et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized, crossover trial. JAMA 2002; 287: 719–25.
52. Balhara Y.P., Sarkar S., Gupta R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian J Endocrinol Metab 2015; 19 (4): 451–61.
53. Trukhan D.I., Viktorova I.A. Bolezni pochek i mochevykh putei. M.: Prakticheskaia meditsina, 2011. [in Russian]
54. Cheitlin MD, Hutter AM, Brindis RG et al. ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. Am Coll Cardiol 1999; 33: 273–82.
55. DeBusk R, Drory Y, Goldstein I et al. Management of sexual dysfunction in patients with cardiovascular disease: recomendations of the Princeton Consensus Panel. Am Cardiol 2000; 86: 175–81.
56. Rekomendatsii po lecheniiu stabil'noi ishemicheskoi bolezni serdtsa. ESC 2013. http://www.scardio.ru/content/Guidelines/IBS_rkj_7_14.pdf [in Russian]
57. Gupta BP, Murad MH, Clifton MM et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and metaanalysis. Arch Intern Med 2011; 171: 1797–803.
58. Kloner R, Padma-Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005; 17: 209–15.
59. Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction takin antihypertensive therapy. Am J Hematol 2001; 14: 70–3.
60. Kloner RA, Mitchell MI, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol 2002; 167 (4): 176–7.
61. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). http://scardio.ru/content/Guidelines/SSHF-Guidelines-rev.4.0.1.pdf [in Russian]
62. Llisterri JL, Lozano Vidal JV, Aznar Vicente J et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321 (5): 336–41.
63. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002; 4 (3): 202–10.
64. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64 (2): 240–55.
65. Zyrianov S.K. Primenenie ingibitorov fosfodiesterazy 5-go tipa v lechenii patsientov s raznymi somaticheskimi zabolevaniiami: pozitsiia klinitsista (lektsiia). Consilium Medicum. 2014; 10: 131–5. [in Russian]
66. Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: wh ere does it fit in? Curr Urol Rep 2013; 14 (4): 269–78.
67. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9 (1): 134–41.
68. Hakky TS, Jain L. Current use of phosphodiesterase inhibitors in urology. Turk J Urol 2015; 41 (2): 88–92.
69. Gumrah A, Tanidir Y, Tinay I et al. The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction. Neurourol Urodyn 2016. DOI: 10.1002/nau.23155 [Epub ahead of print]
70. Trukhan D.I. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Handbook for Practitioners Doctors. 2012; 4: 32–6. [in Russian]
71. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
72. Opisanie lekarstvennogo preparata Vizarsin® (Vizarsin®). URL: https://www.vidal.ru/drugs/vizarsin__30488 [in Russian]
73. Vizarsin® Ku-tab (Vizarsin® Q-tab), instruktsiia po primeneniiu. URL: https://www.vidal.ru/drugs/vizarsin_q-tab__42724 [in Russian]

Д.Г.Макушин*1,2, Д.И.Трухан2

1 ФГБУЗ «Западно-Сибирский медицинский центр» ФМБА России. 644000, Россия, Омск, ул. Красный Путь, д. 127а;
2 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*dmg1@mail.ru

________________________________________________

D.G.Makushin*1,2, D.I.Trukhan2

1 West-Siberian Medical Center. 644000, Russian Federation, Omsk, ul. Krasnyi Put', d. 127a;
2 Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, 12
*dmg1@mail.ru